Introduction of key aspects about HepatiC, a Clinical Patient Registry to monitor HCV-infected patients, from screening to treatment outcome, co-factors, HCC screening and NASH suspected cases

1. A dedicated tool for
HCV-infected patient
care & treatment

2. WHY ?
 New direct antiviral agents
(DAAs)
 Interferon-free based Rx / Promise of HCV
cure
 Numerous clinical trials
 New Rx strategies will happen
 Large estimates of HCV-infected
pts
 Few are diagnosed, Patient status
 More is needed
 Post-treatment and HCV cure assessment
 Progression or not to HCC and
transplantation
What ?
 Web-based platform
 Collaborative, multi-user, multi-site
 HCV-infected patients
 Data collection and analysis
 Routine & research
 Developed by ABL together
with the AEEH (Asociacion
Espanola para el Estudio del
Higado) (Spain) for research in
November 2013

3. • Features
• Draft mode for saving data
without all mandatory information
• No nominative data to create a
patient
• Printing a PDF for Patient
Summary with a bar code
• Data export
• Patient details
 Demographics (site, age, gender,
unique ID, lifestyle and education)
 Residence information for
epidemiological survey
 Virus (genotype and subtype) and
death
• Standard visit
 General status with detailed vitals
 All non invasive testing
 Upper endoscopy
 Extended list of laboratory tests
 Including HBV and HIV
 Ability to determine results with
upper limit normal for lab test
 From naïve to harder to treat
patients
 Treatment (include all the
interferon, ribavirin and DAAs)
 Pre-treatment and new treatment course
 Treatment status (dosing, continue, stop,
discontinuation)
 Adverse events per drug or for all the drug
 Outcome (SVR, failure, …)

4. Any HCV +
Patient
Demographics
Identification,
Gender
Residence
Geno/Subtype,
IL28, Death
Any visit
Naïve, Pre-
treated
Rx history
Vitals Labs/Procedure
Biopsy
FibroScan™
FibroTest™
Endoscopy
On treatment
Type/Dosing
AEs
Outcome

5. Ronan Boulmé
ronan@ablsa.com